Granulomatous interstitial nephritis treated with a tumour necrosis factor-alpha inhibitor.
Tomlinson
Laurie
L
Brighton and Sussex Medical School, University of Sussex, Falmer, Sussex, BN 9PX, UK.
Davies
Kevin
K
Wright
David A
DA
Holt
Stephen
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D003951:Diagnostic Errors; D004392:Dwarfism / Q000139:chemically induced; D006099:Granuloma / Q000188:drug therapy* / Q000473:pathology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D009395:Nephritis, Interstitial / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009402:Nephrosis, Lipoid / Q000175:diagnosis; D009404:Nephrotic Syndrome / Q000209:etiology; D009765:Obesity / Q000139:chemically induced; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D011628:Puberty, Delayed / Q000139:chemically induced; D012008:Recurrence; D012074:Remission Induction; D016559:Tacrolimus / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D011239:Prednisolone; D000069285:Infliximab; D016559:Tacrolimus